Cancer Risks Associated With Germline Mutations in <emph type="ital">MLH1</emph>, <emph type="ital">MSH2</emph>, and <emph type="ital">MSH6</emph> Genes in Lynch Syndrome
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
CONTEXT: Providing accurate estimates of cancer risks is a major challenge in the clinical management of Lynch syndrome. OBJECTIVE: To estimate the age-specific cumulative risks of developing various tumors using a large series of families with mutations of the MLH1, MSH2, and MSH6 genes. DESIGN, SETTING, AND PARTICIPANTS: Families with Lynch syndrome enrolled between January 1, 2006, and December 31, 2009, from 40 French cancer genetics clinics participating in the ERISCAM (Estimation des Risques de Cancer chez les porteurs de mutation des gènes MMR) study; 537 families with segregating mutated genes (248 with MLH1; 256 with MSH2; and 33 with MSH6) were analyzed. MAIN OUTCOME MEASURE: Age-specific cumulative cancer risks estimated using the genotype restricted likelihood (GRL) method accounting for ascertainment bias. RESULTS: Significant differences in estimated cumulative cancer risk were found between the 3 mutated genes (P = .01). The estimated cumulative risks of colorectal cancer by age 70 years were 41% (95% confidence intervals [CI], 25%-70%) for MLH1 mutation carriers, 48% (95% CI, 30%-77%) for MSH2, and 12% (95% CI, 8%-22%) for MSH6. For endometrial cancer, corresponding risks were 54% (95% CI, 20%-80%), 21% (95% CI, 8%-77%), and 16% (95% CI, 8%-32%). For ovarian cancer, they were 20% (95% CI, 1%-65%), 24% (95% CI, 3%-52%), and 1% (95% CI, 0%-3%). The estimated cumulative risks by age 40 years did not exceed 2% (95% CI, 0%-7%) for endometrial cancer nor 1% (95% CI, 0%-3%) for ovarian cancer, irrespective of the gene. The estimated lifetime risks for other tumor types did not exceed 3% with any of the gene mutations. CONCLUSIONS: MSH6 mutations are associated with markedly lower cancer risks than MLH1 or MSH2 mutations. Lifetime ovarian and endometrial cancer risks associated with MLH1 or MSH2 mutations were high but do not increase appreciably until after the age of 40 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VASEN, H., WATSON, P., MECKLIN, J., & LYNCH, H. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70510-x · Cited by 2,519
Lynch, H. T., & de la Chapelle, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012242 · Cited by 2,203
Meta-Analysis of BRCA1 and BRCA2 Penetrance
Chen, S., & Parmigiani, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.1066 · Cited by 1,802
Järvinen, H. J., Aarnio, M., Mustonen, H., Aktan–Collan, K., Aaltonen, L. A., Peltomäki, P., Chapelle, A. D. L., & Mecklin, J. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70168-5 · Cited by 1,337
Cancer risk in mutation carriers of DNA-mismatch-repair genes
Aarnio, M., Sankila, R., Pukkala, E., Salovaara, R., Aaltonen, L. A., de la Chapelle, A., Peltom�ki, P., Mecklin, J.-P., & J�rvinen, H. J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990412)81:2<214::aid-ijc8>3.0.co;2-l · Cited by 1,278
Rodriguez-Bigas, M. A., Boland, C. R., Hamilton, S. R., Henson, D. E., Srivastava, S., Jass, J. R., Khan, P. M., Lynch, H., Smyrk, T., Perucho, M., et al. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.23.1758 · Cited by 1,137
Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome
Schmeler, K. M., Lynch, H. T., Chen, L.-M., Munsell, M. F., Soliman, P. T., Clark, M. B., Daniels, M. S., White, K. G., Boyd-Rogers, S. G., Conrad, P. G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052627 · Cited by 794
Cancer risk associated with germline DNA mismatch repair gene mutations
Dunlop, M. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.1.105 · Cited by 688
Lindor, N. M., Petersen, G. M., Hadley, D. W., Kinney, A. Y., Miesfeldt, S., Lu, K. H., Lynch, P., Burke, W., & Press, N. (2006) · JAMA · doi:10.1001/jama.296.12.1507 · Cited by 629
The risk of extra‐colonic, extra‐endometrial cancer in the Lynch syndrome
Watson, P., Vasen, H. F. A., Mecklin, J., Bernstein, I., Aarnio, M., Järvinen, H. J., Myrhøj, T., Sunde, L., Wijnen, J. T., & Lynch, H. T. (2008) · International Journal of Cancer · doi:10.1002/ijc.23508 · Cited by 596
Cited by
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors
Rawla, P., Sunkara, T., & Barsouk, A. (2019) · Gastroenterology Review · doi:10.5114/pg.2018.81072 · Cited by 2,323
Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L., & Burt, R. W. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.435 · Cited by 1,662
Epidemiology of ovarian cancer: a review
Brett M., R., Brett M., R., Jennifer B., P., Thomas A., S., Jennifer B., P., & Thomas A., S. (2017) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0084 · Cited by 1,524
Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N., & Darai, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00130-0 · Cited by 1,514
Cancer statistics for adolescents and young adults, 2020
Miller, K. D., Fidler‐Benaoudia, M., Keegan, T. H., Hipp, H. S., Jemal, A., & Siegel, R. L. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21637 · Cited by 1,190
Vasen, H. F. A., Blanco, I., Aktan-Collan, K., Gopie, J. P., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., Burn, J., Capella, G., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-304356 · Cited by 746
Self-citationMakker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Dominguez-Valentin, M., Sampson, J. R., Seppälä, T. T., ten Broeke, S. W., Plazzer, J.-P., Nakken, S., Engel, C., Aretz, S., Jenkins, M. A., Sunde, L., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-019-0596-9 · Cited by 662
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
Latham, A., Srinivasan, P., Kemel, Y., Shia, J., Bandlamudi, C., Mandelker, D., Middha, S., Hechtman, J., Zehir, A., Dubard-Gault, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00283 · Cited by 616
Hampel, H., Bennett, R. L., Buchanan, A., Pearlman, R., & Wiesner, G. L. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.147 · Cited by 587
Giardiello, F. M., Allen, J. I., Axilbund, J. E., Boland, C. R., Burke, C. A., Burt, R. W., Church, J. M., Dominitz, J. A., Johnson, D. A., Kaltenbach, T., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.04.001 · Cited by 558
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J., & Cervantes, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 528
Monahan, K. J., Bradshaw, N., Dolwani, S., Desouza, B., Dunlop, M. G., East, J. E., Ilyas, M., Kaur, A., Lalloo, F., Latchford, A., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319915 · Cited by 484
Giardiello, F. M., Allen, J. I., Axilbund, J. E., Boland, R. C., Burke, C. A., Burt, R. W., Church, J. M., Dominitz, J. A., Johnson, D. A., Kaltenbach, T., et al. (2014) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.186 · Cited by 483
InSiGHT, O. B. O., Thompson, B. A., Spurdle, A. B., Plazzer, J.-P., Greenblatt, M. S., Akagi, K., Al-Mulla, F., Bapat, B., Bernstein, I., Capellá, G., et al. (2014) · Nature Genetics · doi:10.1038/ng.2854 · Cited by 467
Endometrial cancer: A review and current management strategies: Part II
Burke, W. M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A. B., Brewer, M., Boruta, D., Herzog, T. J., & Shahin, F. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.06.003 · Cited by 459
Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions
Fahed, A. C., Wang, M., Homburger, J. R., Patel, A. P., Bick, A. G., Neben, C. L., Lai, C., Brockman, D., Philippakis, A., Ellinor, P. T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17374-3 · Cited by 455
Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer
Kawakami, H., Zaanan, A., & Sinicrope, F. A. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0348-2 · Cited by 418
Yamashita, R., Long, J., Longacre, T., Peng, L., Berry, G., Martin, B., Higgins, J., Rubin, D. L., & Shen, J. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30535-0 · Cited by 391
Endometrial cancer: A review and current management strategies: Part I
Burke, W. M., Orr, J., Leitao, M., Salom, E., Gehrig, P., Olawaiye, A. B., Brewer, M., Boruta, D., Villella, J., Herzog, T., et al. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.05.018 · Cited by 390
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
Konstantinopoulos, P. A., Norquist, B., Lacchetti, C., Armstrong, D., Grisham, R. N., Goodfellow, P. J., Kohn, E. C., Levine, D. A., Liu, J. F., Lu, K. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02960 · Cited by 381
Hereditary breast and ovarian cancer: new genes in confined pathways
Nielsen, F. C., van Overeem Hansen, T., & Sørensen, C. S. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.72 · Cited by 367
Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., Horick, N., Yang, S., Shannon, K. M., Tung, N., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2690 · Cited by 333
Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome
Engel, C., Loeffler, M., Steinke, V., Rahner, N., Holinski-Feder, E., Dietmaier, W., Schackert, H. K., Goergens, H., von Knebel Doeberitz, M., Goecke, T. O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2278 · Cited by 306
Caruso, G., Weroha, S. J., & Cliby, W. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 304
Lancaster, J. M., Powell, C. B., Chen, L.-M., & Richardson, D. L. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.09.009 · Cited by 298
Ovarian Cancer Prevention and Screening
Menon, U., Karpinskyj, C., & Gentry-Maharaj, A. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002580 · Cited by 279
Lynch Syndrome–Associated Colorectal Cancer
Sinicrope, F. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1714533 · Cited by 279
Seppälä, T. T., Latchford, A., Negoi, I., Sampaio Soares, A., Jimenez-Rodriguez, R., Sánchez-Guillén, L., Evans, D. G., Ryan, N., Crosbie, E. J., Dominguez-Valentin, M., et al. (2021) · British Journal of Surgery · doi:10.1002/bjs.11902 · Cited by 275
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
Travis, L. B., Wahnefried, W. D., Allan, J. M., Wood, M. E., & Ng, A. K. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.41 · Cited by 264
Castéra, L., Krieger, S., Rousselin, A., Legros, A., Baumann, J.-J., Bruet, O., Brault, B., Fouillet, R., Goardon, N., Letac, O., et al. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.16 · Cited by 262
Risks of Primary Extracolonic Cancers Following Colorectal Cancer in Lynch Syndrome
Win, A. K., Lindor, N. M., Young, J. P., Macrae, F. A., Young, G. P., Williamson, E., Parry, S., Goldblatt, J., Lipton, L., Winship, I., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs351 · Cited by 254
Engineering patient-specific cancer immunotherapies
Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208
Talhouk, A., & McAlpine, J. N. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0035-4 · Cited by 205
“Although all MMR deficiencies are often grouped together, for inherited mutations (Lynch syndrome), the lifetime risk and age of penetration of Lynch-associated cancers can vary substantially according which gene is aberrant [90].”
BackgroundValle, L., Vilar, E., Tavtigian, S. V., & Stoffel, E. M. (2019) · The Journal of Pathology · doi:10.1002/path.5229 · Cited by 203
Relevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal Carcinomas
Funkhouser, W. K., Lubin, I. M., Monzon, F. A., Zehnbauer, B. A., Evans, J. P., Ogino, S., & Nowak, J. A. (2012) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2011.11.001 · Cited by 189
Lu, H.-M., Li, S., Black, M. H., Lee, S., Hoiness, R., Wu, S., Mu, W., Huether, R., Chen, J., Sridhar, S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2956 · Cited by 178
Hampel, H., Pearlman, R., Beightol, M., Zhao, W., Jones, D., Frankel, W. L., Goodfellow, P. J., Yilmaz, A., Miller, K., Bacher, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0104 · Cited by 172
Grosse, S. D., Gurrin, L. C., Bertalli, N. A., & Allen, K. J. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.121 · Cited by 76
Randrian, V., Evrard, C., & Tougeron, D. (2021) · Cancers · doi:10.3390/cancers13123063 · Cited by 65
“While patients with LS have a cumulative risk of developing CRC of about 40-60% at 70 years old, this rate has been lowered with adequate endoscopic follow-up [19].”
BackgroundHereditary Colorectal Cancer: State of the Art in Lynch Syndrome
Nolano, A., Medugno, A., Trombetti, S., Liccardo, R., De Rosa, M., Izzo, P., & Duraturo, F. (2022) · Cancers · doi:10.3390/cancers15010075 · Cited by 37
“any LS-associated cancer up to age 70 varies between 57% and nearly 80% for carriers of MSH2 mutations and between 59% and 65% for carriers of MLH1 mutations [69,70].”
BackgroundColorectal cancer screening in Lynch syndrome: Indication, techniques and future perspectives
Perrod, G., Rahmi, G., & Cellier, C. (2021) · Digestive Endoscopy · doi:10.1111/den.13702 · Cited by 28
The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells
Bommi, P. V., Bowen, C. M., Reyes-Uribe, L., Wu, W., Katayama, H., Rocha, P., Parra, E. R., Francisco-Cruz, A., Ozcan, Z., Tosti, E., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2896 · Cited by 10
Metadata
- Authors
- Bonadona, V.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-06-08
- Volume
- 305
- Issue
- 22
- Pages
- 2304
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2159899668
- Cited by
- 1,103
- References
- 31
- FWCI
- 38.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.